The total pass rate of Chinese herbal decoction pieces has increased by over 98%, tending to concentrate the advantages

 As one of the important means of drug post-market supervision, drug sampling is an in-depth "physical examination" of sampling samples
.
Recently, the China National Institute for Food and Drug Control released the "2021 National Drug Sampling Results".
The sampling results show that the total pass rate of traditional Chinese medicine pieces has increased to 98.
4%
.
With the continuous strengthening of special sampling inspections of TCM decoction pieces and the intensification of information disclosure supervision, the industry tends to concentrate its advantages
.
The data shows that from 2017 to 2021, the total pass rate of national drug sampling inspection of Chinese herbal decoction pieces increased from 89.
7% to 98.
4%
.
It is understood that in terms of improving the quality of TCM decoction pieces, the state and local governments have also continuously issued new policies
.
For example, recently, Shanghai issued the "Notice on Carrying out the Pilot Work of Clinical Application of Whole-process Traceability of Traditional Chinese Medicine Pieces in the City", selected 5 Chinese medicine hospitals and 8 pharmaceutical companies in Shanghai as pilots, supported the use of traceable pieces, and encouraged high quality and good prices.
, to improve the quality of traditional Chinese medicine pieces
.
From the perspective of the industry, the establishment of a quality traceability system for Chinese herbal decoction pieces, and the implementation of whole-process management on the production and sales of Chinese herbal decoction pieces, to ensure the safety, effectiveness and traceability of Chinese herbal decoction pieces, are conducive to ensuring the quality of medicines
.
It is reported that in addition to Shanghai and overseas, there are also some places where relevant work has been carried out one after another
.
For example, at the end of last year, Foshan City announced that it would implement quality traceability in the production and operation of Chinese herbal decoction pieces in Guangdong Province
.
By the end of 2021, it has covered 4 production enterprises, 18 wholesale chain enterprises and more than 1,400 retail pharmacies
.
Recently, Anhui also stated that it is studying the informatization traceability of TCM decoction pieces, discussing and researching a series of issues such as the informatization traceability mode, traceability link, traceability content, traceability code management, pilot varieties, and pilot enterprise selection of TCM decoction pieces
.
Decoction pieces of traditional Chinese medicine are one of the three pillars of China's traditional Chinese medicine industry and have vigorous development potential
.
As shown in the data, from 2011 to 2018, the market size of Chinese herbal decoction pieces processing increased from 87.
4 billion yuan to 263.
7 billion yuan, with an average annual compound growth rate of 17.
1%.

.
However, it is worth noting that the traditional Chinese medicine decoction pieces industry also presents problems such as low industrial concentration, fierce competition, and uneven quality
.
The data shows that there are more than 1,000 Chinese herbal medicine processing enterprises in China, most of which are small in scale, with many production varieties, and the industry market concentration is low
.
Among them, according to the "2021 National Drug Sampling Results", there are also many problems with Chinese herbal medicines.
It is worth noting that the problem of traits accounts for 51.
4%, which has become the main problem of unqualified Chinese herbal medicines
.
In addition, the main problems found in the special sampling inspection of Chinese herbal decoction pieces and the quality monitoring of Chinese herbal medicines are: 1.
Substitute and adulteration of fake products 2.
The problem of excessive residues of exogenous harmful substances, some raw materials have hidden dangers such as mycotoxins pollution, pesticide residue pollution, heavy metals and harmful elements exceeding the standard, such as heavy metal residues in individual batches of Atractylodes japonica and woodsy, individual batches Plant growth regulators were detected in the northern ginseng; 3.
The problems of non-standard harvesting, processing and processing, such as the incomplete removal of soil from the production area of ​​Atractylodes, the total ash content of individual samples exceeded the standard limit, and the excessive stems on the ground during the processing of Bupleurum decoction pieces.
Impurities in non-medicinal parts exceeded the standard
.
From the current point of view, although the quality of Chinese herbal decoction pieces is still uneven, the industry said that with the country's continuous emphasis on the Chinese medicine industry, the quality of the Chinese herbal medicine industry will continue to improve
.
For example, the development of centralized procurement may help to standardize the quality of TCM decoction pieces, forcing enterprises to improve product quality
.
In addition, with the development of centralized procurement, the market of Chinese herbal medicine pieces will also realize the survival of the fittest, the industrial concentration can be improved, and a group of enterprises with strength and service capabilities will be formed
.
It is reported that following the joint procurement of the National Inter-Provincial Chinese Medicine (Material) Procurement Alliance this year, Chinese herbal decoction pieces from many places have ushered in centralized procurement
.
For example, recently, the Shanxi Provincial Pharmaceutical Equipment Centralized Bidding Procurement Network issued a notice to organize medical institutions in the province to carry out the centralized procurement of traditional Chinese medicine pieces with volume and fill in the procurement data of related varieties
.
Ningxia and Shandong have also recently issued notices to carry out the reporting of data related to some varieties of Chinese herbal medicines
.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
.